Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
1.
Ann Ist Super Sanita ; 60(1): 47-54, 2024.
Article in English | MEDLINE | ID: mdl-38920258

ABSTRACT

BACKGROUND: The management of Long COVID symptoms is necessary. This study proposes a screening tool for psycho-physical COVID-19 sequelae. Patients' experiences after COVID-19 are also described. METHOD: 84 COVID-19 patients (66.2±11.0 years old; 71.4% male) underwent a phone interview 1-2 years after the disease using the ad-hoc "Post-Acute Sequelae of COVID-19 Checklist (PASC-C)". It explores 30 physical, psychological, and cognitive symptoms clustered into 10 areas, with possible clinical recommendations in case of high severity scores (>50) of a symptom or the presence of two or more ones within the same area. RESULTS: Overall, fatigue (69%), dyspnea (52.4%), memory disturbances (44%), joint-muscle pain (41.7%), vision/hearing loss (40.5%), anxiety (40.5%) persist one-two years after COVID-19 disease. Being a survivor was primarily defined in terms of being "lucky". CONCLUSIONS: PASC-C seems promising in monitoring psycho-physical sequelae of Long COVID and providing tailored suggestions to care for the patient over time.


Subject(s)
Anxiety , COVID-19 , Checklist , Post-Acute COVID-19 Syndrome , Humans , COVID-19/psychology , COVID-19/complications , Male , Female , Middle Aged , Aged , Anxiety/etiology , Anxiety/psychology , Fatigue/etiology , Fatigue/psychology , Dyspnea/etiology , Dyspnea/psychology , Aged, 80 and over , SARS-CoV-2 , Adult
2.
Ann Clin Transl Neurol ; 11(5): 1090-1096, 2024 May.
Article in English | MEDLINE | ID: mdl-38600653

ABSTRACT

OBJECTIVES: Mandatory newborn screening (NBS) for spinal muscular atrophy (SMA) was implemented for the first time in Italy at the end of 2021, allowing the identification and treatment of patients at an asymptomatic stage. METHODS: DNA samples extracted from dried blood spot (DBS) from newborns in Apulia region were analysed for SMA screening by using a real-time PCR-based assay. Infants harbouring homozygous deletion of SMN1 exon 7 confirmed by diagnostic molecular tests underwent clinical and neurophysiological assessment and received a timely treatment. RESULTS: Over the first 20 months since regional NBS introduction, four out of 42,492 (0.009%) screened children were found to carry a homozygous deletion in the exon 7 of SMN1 gene, with an annual incidence of 1:10,623. No false negatives were present. Median age at diagnosis was 7 days and median age at treatment was 20.5 days. Three of them had two copies of SMN2 and received gene therapy, while the one with three SMN2 copies was treated with nusinersen. All but one were asymptomatic at birth, showed no clinical signs of disease after a maximum follow-up of 16 months and reached motor milestones appropriate with their age. The minimum interval between diagnosis and the treatment initiation was 9 days. INTERPRETATION: The timely administration of disease-modifying therapies prevented presymptomatic subjects to develop disease symptoms. Mandatory NBS for SMA should be implemented on a national scale.


Subject(s)
Muscular Atrophy, Spinal , Neonatal Screening , Survival of Motor Neuron 1 Protein , Humans , Italy , Infant, Newborn , Muscular Atrophy, Spinal/diagnosis , Muscular Atrophy, Spinal/genetics , Muscular Atrophy, Spinal/therapy , Survival of Motor Neuron 1 Protein/genetics , Female , Male , Survival of Motor Neuron 2 Protein/genetics , Oligonucleotides/administration & dosage , Oligonucleotides/pharmacology , Infant
3.
Adv Ther ; 40(12): 5338-5353, 2023 12.
Article in English | MEDLINE | ID: mdl-37787877

ABSTRACT

INTRODUCTION: Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV) are rare autoimmune diseases triggering inflammation of small vessels. This real-world analysis was focused on the most common AAV forms, granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), to describe patients' demographic and clinical characteristics, therapeutic management, disease progression, and the related economic burden. METHODS: A retrospective analysis was conducted on administrative databases of a representative sample of Italian healthcare entities, covering approximately 12 million residents. Between January 2010 and December 2020, adult GPA patients were identified by payment waiver code or hospitalization discharge diagnosis, and MPA patients by payment waiver code with or without hospitalization discharge diagnosis. Clinical outcomes were evaluated through AAV-related hospitalizations, renal failure onset, and mortality. Economic analysis included healthcare resource utilization deriving from drugs, hospitalizations, and outpatient specialist services. The related mean direct costs year/patient were also calculated in patients stratified by presence/absence of glucocorticoid therapy and type of inclusion criterion (hospitalization/payment waiver code). RESULTS: Overall, 859 AAV patients were divided into GPA (n = 713; 83%) and MPA (n = 146; 17%) cohorts. Outcome indicators highlighted a clinically worse phenotype associated with GPA compared to MPA. Cost analysis during follow-up showed tendentially increased expenditures in glucocorticoid-treated patients versus untreated (overall AAV: €8728 vs. €7911; GPA: €9292 vs. €9143; MPA: €5967 vs. €2390), mainly driven by drugs (AAV: €2404 vs. €874; GPA: €2510 vs. €878; MPA: €1881 vs. €854) and hospitalizations. CONCLUSION: Among AAV forms, GPA resulted in a worse clinical picture, higher mortality, and increased costs. This is the first real-world pharmaco-economic analysis on AAV patients stratified by glucocorticoid use on disease management expenditures. In both GPA and MPA patients, glucocorticoid treatment resulted in higher healthcare costs, mostly attributable to medications, and then hospitalizations, confirming the clinical complexity and economic burden for management of patients with autoimmune diseases under chronic immunosuppression.


Subject(s)
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis , Microscopic Polyangiitis , Adult , Humans , Retrospective Studies , Glucocorticoids , Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/drug therapy , Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/complications , Microscopic Polyangiitis/therapy , Health Care Costs
4.
Healthcare (Basel) ; 11(18)2023 Sep 10.
Article in English | MEDLINE | ID: mdl-37761706

ABSTRACT

This real-world analysis investigated the characteristics and treatment patterns of patients with hereditary angioedema (HAE) in Italy using the administrative data of health units across Italy. Patients were identified via exemption code or HAE-specific treatments (thus, all known forms, type I, II and, III, were included). The index date was that of first prescription of HAE treatments within the inclusion period (01/2010-06/2021) or of the date of exemption. The number of HAE patients included was 148 (43.2% male, mean age 43.3 years). Gastrointestinal disorders affected 36.5% patients, hypertension affected 28.4%, hypercholesterolemia affected 11.5%, and depression affected 9.5%. The frequent gastrointestinal involvement was further confirmed by the use of antiemetics and systemic antihistamines that doubled after the index date. Among patients enrolled by treatment (n = 125), n = 105 (84%) were receiving a treatment for acute attacks. This analysis provided insights into the characterization of patients with HAE and their management in Italian clinical practice, suggesting that an unmet therapeutic need could be present for such patients in terms of the clinical burden.

5.
Seizure ; 42: 20-28, 2016 Nov.
Article in English | MEDLINE | ID: mdl-27693808

ABSTRACT

PURPOSE: to evaluate the efficacy and safety of intravenous (IV) lacosamide (LCM) in the treatment of seizure clusters (SC) and status epilepticus (SE) in hospitalized adult patients. METHODS: we prospectively analyzed treatment response, seizure outcome, and adverse effects of IV LCM in 38 patients with seizure emergencies (15 with SC, 23 with SE) during a hospital stay. The loading dose of IV LCM was 200-400mg and the maintenance dose was 200-400mg daily. Response to IV LCM was evaluated within 20min, 4h and 24h of LCM infusion. RESULTS: an acute anti-seizure effect after IV LCM was especially evident when it was first used - (SC) or second line (established SE) treatment. In particular, 87% of SC patients (13/15) and 80% of established SE (8/10) demonstrated response to LCM treatment, while no patients with super-refractory SE (0/8) responded to IV LCM according to our criteria. The loading of IV LCM was well tolerated, with mild adverse effects (2/38 temporary dizziness). In most patients, during and after administration of the loading dose of IV LCM a temporary (30min-1h) sedation was observed. No ECG and laboratory values-changes were documented in any of the patients. CONCLUSIONS: LCM is an effective and well-tolerated treatment when used to treat SC in hospitalized adult patients. As add-on therapy, it may be useful to stop seizure activity in patients with focal SE not responding to first/second-line intravenous AEDs.


Subject(s)
Acetamides/administration & dosage , Anticonvulsants/administration & dosage , Seizures/drug therapy , Status Epilepticus/drug therapy , Acetamides/adverse effects , Administration, Intravenous , Adult , Aged , Aged, 80 and over , Anticonvulsants/adverse effects , Brain/diagnostic imaging , Brain/physiopathology , Electroencephalography , Female , Hospitalization , Humans , Inpatients , Lacosamide , Male , Middle Aged , Prospective Studies , Seizures/diagnostic imaging , Seizures/physiopathology , Status Epilepticus/diagnostic imaging , Status Epilepticus/physiopathology , Treatment Outcome
6.
Pest Manag Sci ; 72(8): 1537-9, 2016 Aug.
Article in English | MEDLINE | ID: mdl-26537744

ABSTRACT

BACKGROUND: Plasmopara viticola is controlled by fungicides with different modes of action, including carboxylic acid amides (CAAs). The aim of this study was to evaluate differences in the response of CAA-resistant P. viticola strains towards CAAs. RESULTS: The G1105S mutation affects all four CAAs, but with different impacts. While this confirms that they have the same mode of action, it shows that differences between CAAs can occur. CONCLUSION: Further molecular modelling and docking studies are needed to gain a better understanding of the different behaviours reported here. © 2015 Society of Chemical Industry.


Subject(s)
Amides/pharmacology , Drug Resistance, Fungal , Fungicides, Industrial/pharmacology , Oomycetes/drug effects , Amides/chemistry , Fungicides, Industrial/chemistry , Mutation , Oomycetes/genetics , Plant Leaves/microbiology , Vitis/microbiology
8.
São Paulo; s.n; 2001. 36 p. ilus.
Monography in Portuguese | LILACS, Sec. Est. Saúde SP, SESSP-IDPCPROD, Sec. Est. Saúde SP | ID: biblio-1069076

ABSTRACT

Este estudo realizado no Instituto Dante Pazanese de Cardiologia,com o objetivo de identificar clinicamente as características definidoras do diagnóstico de enfermagem de ansiedade em indivíduos com indicação de revascularização do miocárdio.A amostra foi composta por 16 indinvíduos abordados duas vezes : 48 horas após a admissão e nas 24 que antecederam a cirurgia.A análise foi descritiva,baseada nas frequências absolutas e relativas das respostas obtidas dos indivíduos e da pesquisadora, através do teste não paramétrico de Wilcoxon, considerando a linha de corte no valor de P

Subject(s)
Humans , Anxiety , Nursing Diagnosis
SELECTION OF CITATIONS
SEARCH DETAIL
...